Artemisinin-Based Combination Therapy: Clinical Trials in Cameroon
This study has been completed.
Sponsor:
Gates Malaria Partnership
Collaborators:
University of Yaounde
Health Board, Cameroon Baptist Convention, Cameroon
Information provided by (Responsible Party):
Dr Wilfred Mbacham, Gates Malaria Partnership
ClinicalTrials.gov Identifier:
NCT00297882
First received: February 28, 2006
Last updated: April 28, 2013
Last verified: April 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This proposal aims to evaluate the safety and efficacy of artemisinin-based anti-malaria combination drugs (ACTs)for treatment of children aged 1-10 years in different locations in Cameroon. Randomized clinical trials will provide local data on the safety of the test drugs, and on putative marker mutations of the development of resistance to ACT. The study will involve three centres, namely, Banso (Guinea-Savannah region), Limbe(Littoral Forest), and Garoua(Sahel-Savannah). The trial will compare the efficacy and safety of Amodiaquine(AQ)-Artesunate(Art) with Coartem®(Artemether-Lumefantrine). Drug efficacy will be determined using a WHO standardised 28 day protocol. Safety will be monitored through clinical examination, and biochemical and haematological indices. Molecular markers of artemisinin resistance will be investigated by molecular sequencing and comparison of parasite profiles of the PfATP6 gene in drug failure cases, . Recrudescences or re-infections will be assessed by analysis of the msp1 and msp2 genes. The impact of these combinations on generation of gametocytes will be determined from gametocyte carriage rates measured by microscopy.
| Condition | Intervention | Phase |
|---|---|---|
|
Malaria |
Drug: Artemether-Lumefantrine , Amodiaquine-Artesunate |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Subject) Primary Purpose: Treatment |
| Official Title: | Phase III Clinical Trials of Artemisinin-based Combination Therapy in Cameroon |
Resource links provided by NLM:
Further study details as provided by Gates Malaria Partnership:
Primary Outcome Measures:
- Cure rate on Day 28 [ Time Frame: Day 1, 2, 3, 7, 14, 28 ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- Cure rate on Day 14 [ Time Frame: Day 1, 2, 3, 7, 14 ] [ Designated as safety issue: Yes ]
- Adverse Events by Day 28 [ Time Frame: Day 1, 2, 3, 7, 14, 28 ] [ Designated as safety issue: Yes ]
| Enrollment: | 900 |
| Study Start Date: | July 2006 |
| Study Completion Date: | July 2009 |
| Primary Completion Date: | April 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: 1 Artemether-Lumefantrine |
Drug: Artemether-Lumefantrine , Amodiaquine-Artesunate
Other Name: CoArtem, Arsucam
|
| Active Comparator: 2 Amodiaquine-Artemether |
Drug: Artemether-Lumefantrine , Amodiaquine-Artesunate
Other Name: CoArtem, Arsucam
|
Detailed Description:
- Out patients will be screened for malaria by blood film examination
- Malaria-positive children will be examined by the physician for inclusion or exclusion(see below)
- Informed consent will be sought from guardians of potential patients
- Patients or guardians will be interviewed and a case record form completed
- Patients will be randomised into one of the two arms in the ratio 4:1 AQ/Art: CoArtem and issued a study card
- Filter paper and 5ml venous blood samples will be collected
- Patients will be hospitalised for three days to allow completion of therapy under observation
- The patient will be asked to return on days 7, 14 and 28 for assessment of clearance or recrudescence of parasites
- Patient will be examined for parasites and evaluated for early treatment failure (ETF), late treatment failure (LTF), late parasitological failure (LPF) or adequate clinical and parasitological response.(ACPR).
- If a patient does not appear for follow up, a community health worker will try to trace them and will collect blood onto filter paper and a microscope slide should the patient have a temperature ≥ 37.5°C
- Patients whose parents opt out of the study will be administered quinine sulphate if parasitaemic
- Filter paper samples will be air dried and stored with dessicant until required.
- Whole blood samples collected into citrate as anticoagulant will be processed for plasma, aliquoted into 300µl lots and stored at -70°C.
- Patient information will be entered at the close of each day into laptops and collectively sent to Yaounde at the end of the first month of study and thereafter at the end of each week, along with the hard copies of the case report forms.
- Analysis will be performed on the samples within three months of collection for molecular markers of resistance, genetic structure of parasites and for blood drug levels of medications used in the trial
Eligibility| Ages Eligible for Study: | 12 Months to 120 Months |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion criteria:
- children aged 1-10 years;
- axillary temperature ≥ 37.5°C and/or history of fever within past 24 hours;
- P. falciparum asexual parasitaemia between 1000 and 100000/µl;
- ability to attend follow-up visits.
Exclusion criteria:
- co-infections;
- underlying chronic disease;
- severe malaria as indicated by hyperparasitaemia, severe anaemia(PCV 15%, Hb 5g/ml), respiratory distress, inability to drink, persistent vomiting in past 24 hours;
- recent history of multiple convulsions;
- jaundice;
- inability to stand or sit;
- history of allergy to study drug.
Contacts and Locations More Information
No publications provided
| Responsible Party: | Dr Wilfred Mbacham, PI, Gates Malaria Partnership |
| ClinicalTrials.gov Identifier: | NCT00297882 History of Changes |
| Other Study ID Numbers: | ITCRVG46 |
| Study First Received: | February 28, 2006 |
| Last Updated: | April 28, 2013 |
| Health Authority: | Cameroon: Ministry of Public Health |
Keywords provided by Gates Malaria Partnership:
|
Efficacy Safety Children Cameroon |
Additional relevant MeSH terms:
|
Malaria Protozoan Infections Parasitic Diseases Amodiaquine Artemether Artemisinins Artesunate Lumefantrine Artemether-lumefantrine combination Amodiaquine, artesunate drug combination Artemisinine Antimalarials |
Antiprotozoal Agents Antiparasitic Agents Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Antifungal Agents Coccidiostats Schistosomicides Antiplatyhelmintic Agents Anthelmintics Amebicides |
ClinicalTrials.gov processed this record on May 19, 2013